| 产品详情 |
| Edit |   |
|---|
| Product Name | WEHI164 |
|---|
| Description | this line was originally established by M. Rollinghoff and N.L. Warner from a fibrosarcoma induced by subcutaneous injections of 3-methylcholanthrene; after pretreatment with actinomycin D, the cells are highly sensitive to human cytotoxic monocytes, to human tumor necrosis factor and to lymphotoxin; they can be used as target cells for short term chromium release cytotoxicity assays; tested and found negative for ectromelia virus (mousepox)Tumorigenecity:Isoenzyme:Histopathology:fibrosarcomaSubculture:Split ratio:Media change:Reverse transcritase:Production |
|---|
| Size | 1 vial |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | ABC-TC1284 |
|---|
| Price | |
|---|
| Order / More Info | WEHI164 from ACCEGEN BIOTECH |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|